Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study

Denschlag D, Czogalla B, Heitz F, Kerkmann M, Fangmann LC, Klecker PH, Stübs F, Wölber L, Radosa J, Lodde PC, Seitz S, George C, Mach P, Fink A, Bokhua D, Degregorio N, Lampe B, Hemptenmacher F, Friebe V, Fleisch M, Wimberger P, Jaeger A, Schnelzer A, Mittelstadt S, Ratiu D, Eichbaum M, Haus A, Kalder M, Ataseven B, Schröder W, Bronger H, Kosse J, Ulrich UA, Elser G, Harter P (2025)

Publication Type: Journal article

Publication year: 2025

Journal

Book Volume: 85

Pages Range: 520-532

Journal Issue: 5

DOI: 10.1055/a-2520-5736

Abstract

Introduction Real-world data on treatment patterns and outcomes in recurrent or metastatic cervical cancer (r/mCC) are lacking. Methods This first national quality assurance initiative was a retrospective analysis of patients with r/mCC diagnosed between 2018 and 2022, who were identified from medical records of 31 gynecologic cancer centers in Germany. Patient demographic and clinical characteristics, treatment patterns, and clinical outcomes were assessed descriptively. Progression-free (PFS) and overall survival (OS) were calculated using Kaplan-Meier analysis. Results A total of 503 eligible patients (median age 55 years) were analyzed for r/mCC. 276/503 patients (55%) received first-line (1L) chemotherapy (platinum combination: 247/276; 79%) followed by targeted antibody therapy with bevacizumab (177/247; 72%), immunotherapy (19/247; 8%), or both combined (50/247; 20%). 111/503 (22%) received chemotherapy only (platinum combination: 64/111; 58%, platinum mono: 35/111; 31%, or platinum-free: 12/111; 11%), and 110/503 (22%) did not receive any systemic treatment (the remaining 6/503 patients received immunotherapy only). For these subgroups after a median follow-up of 16 months, the PFS was 12 months (95% CI 11-14), 8.8 months (95% CI 7.1-11), and 3 months (95% CI 2.3-4.8), and OS was 25 months (95% CI 21-31), 17 months (95% CI 14-22), and 3.6 months (95% CI 2.8-5.3), respectively. 176/283 (62%) patients who developed progressive disease (PD) were treated with second-line (2L) therapy. Conclusion Only half of the patients with r/mCC were treated 1L with platinum-combination therapy including antibody therapy according to national guidelines. Moreover, 22% at initial diagnosis and 38% of patients at PD were not treated with systemic therapy at all. This might reflect poor general performance status, patients' preference, and/or lack of effective therapies especially in 2L treatment.

Authors with CRIS profile

Involved external institutions

Hochtaunus-Kliniken Germany (DE) Klinikum der Universität München Germany (DE) Kliniken Essen-Mitte Germany (DE) MMF GmbH Germany (DE) Universität Regensburg Germany (DE) Universitätsmedizin Rostock Germany (DE) Universitätsklinikum Essen Germany (DE) Universitätsklinikum Ulm Germany (DE) Universitätsklinikum Jena Germany (DE) SLK-Kliniken Heilbronn GmbH Germany (DE) Städtische Kliniken Mönchengladbach GmbH / Elisabeth-Krankenhaus Rheydt Germany (DE) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Universitätsklinikum Düsseldorf Germany (DE) HELIOS Kliniken Germany (DE) Universität Bielefeld Germany (DE) Technische Universität Dresden Germany (DE) Klinikum rechts der Isar Germany (DE) Sana Kliniken AG Germany (DE) Martin-Luther-Krankenhaus Germany (DE) Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) RoMed Kliniken - Kliniken der Stadt und des Landkreises Rosenheim GmbH Germany (DE) Diakonie-Klinikum Schwäbisch Hall Germany (DE) Universitätsklinikum Köln Germany (DE) Horst-Schmidt-Kliniken Germany (DE) GPR Gesundheits- und Pflegezentrum Rüsselsheim gemeinnützige GmbH Germany (DE) Gynaekologicum Bremen Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) Germany (DE) Universitätsklinikum des Saarlandes (UKS) Germany (DE) Universitätsklinikum Bonn Germany (DE)

How to cite

APA:

Denschlag, D., Czogalla, B., Heitz, F., Kerkmann, M., Fangmann, L.C., Klecker, P.H.,... Harter, P. (2025). Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study. Geburtshilfe und Frauenheilkunde, 85(5), 520-532. https://doi.org/10.1055/a-2520-5736

MLA:

Denschlag, Dominik, et al. "Evaluation of Baseline Characteristics and Therapeutic Management Strategies in Metastatic Cervical Cancer in Germany: A Multicentric Retrospective Longitudinal Observational Study." Geburtshilfe und Frauenheilkunde 85.5 (2025): 520-532.

BibTeX: Download